Buformin-d9 (hydrochloride)

Buformin-d9 (hydrochloride)

• UNSPSC Description: Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al)[1].
• Target Antigen: AMPK; Isotope-Labeled Compounds
• Type: Isotope-Labeled Compounds
• Related Pathways: Epigenetics;Others;PI3K/Akt/mTOR
• Field of Research: Cancer; Metabolic Disease
• Solubility: 10 mM in DMSO
• Smiles: N=C(N)NC(NC([2H])([2H])C([2H])([2H])C([2H])([2H])C([2H])([2H])[2H])=N.[H]Cl
• Molecular Weight: 202.73
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. |[2]Amanda B Parris, et al. Buformin Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res|[3]Jing Li, et al. Buformin Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517.
• Shipping Conditions: Room temperature
• Clinical Information: No Development Reported